Choivo, the allowance for impairment loss on receivables actually increases 21% as compared to revenue increase of 8%. This allowance is acceptable as their lending is mainly to civil workers and repayment is done through salary deduction. Mbsb and Aeoncr might be their closest peer but there is still difference in the business nature between those companies.
Keep BUY with a higher MYR2.20 TP from MYR2.10, 30% upside with 6% yield. RCE Capital’s 9MFY20 (Mar) net earnings beat estimates. Resilient receivable growth, lower funding costs, and well-contained credit costs were the main drivers. Valuation remains attractive, as the stock is currently trading at a mere 0.8x FY21F P/BV. Our revised TP values RCE at a GGM-derived FY21F P/BV of 1.07x against a projected FY20-22F average ROE of 16%.  9MFY20 beat. RCE raked in MYR82.2m in PATAMI for 9MFY20, which accounted for 79% and 83% of our and Street’s estimates. YTD PIOP grew 9% YoY, mainly lifted by robust topline growth, with NII and non-II growing 11% and 6%. Opex grew 13% YoY, but the overall CIR ratio remained well controlled at 23.1% (+6ppts YoY). Net earnings expanded faster YoY at 14.6%, thanks to 15% lower impairment charges. Credit cost improved to 112bps from 139bps over a year ago. Asset quality remained healthy, with both NPL and GIL ratios down 15bps and 26bps QoQ.  3QFY20 PATAMI jumped 23% YoY (+14% QoQ). Overall business operations remained solid. NII grew 4.7% QoQ, buoyed by a 17bps expansion in NIM, based on our estimates. Lower cost of funds – from a sukuk issuance – contributed to the sequential improvement in margins, while the lending rate was steady QoQ. CIR improved c.260bps QoQ to 20.3% on lower staff costs and other expenses. Consequently, PIOP grew 7.6% QoQ. Impairment charges fell 18% QoQ – a testament to RCE’s prudent underwriting policies and consistent recovery. Quarterly annualised credit costs further improved to 104bps from 128bps in 2QFY20. ROE stood a high 19.5% in 3QFY20 (9MFY20: 18.1%).  Receivables growth resilient. Gross receivables expanded 5% YoY (+1.6% QoQ) to MYR1.8bn. RCE looks set to achieve its mid-single digit growth target for FY20. Management has not seen any slowdown in lending activities despite the softening macroeconomic environment. Applications remain robust, with no signs of a meaningful slowdown.  Earnings and TP. We tweaked our FY20-21F earnings by c.4% for FY20-21F to account for slightly higher other income. Our TP is revised on the positive earnings revision. We value RCE at a GGM-derived FY21F P/BV of 1.07x against a projected FY20-22F average ROE of 16%.  The downside risks to our recommendation include higher credit costs, and weaker net financing margins and growth in receivables.
=== Gidstock Choivo, the allowance for impairment loss on receivables actually increases 21% as compared to revenue increase of 8%. This allowance is acceptable as their lending is mainly to civil workers and repayment is done through salary deduction. Mbsb and Aeoncr might be their closest peer but there is still difference in the business nature between those companies. 19/02/2020 10:34 AM
feel free to collect on weakness for the strong results, good DY and continuous delivery Quarter after quarter. We like it and will continue to hold it until the market realises its potential. Many have said RCE Cap share price will not go up because it has large debts. Please be reminded that RCE Cap is a finance company, raising debts to disburse loan - its the core business. Just as how a bank operates. With a low IR environment, their cost of borrowing is higher. As long NPL is not high, they will do fine. (Please note that RCE gives loan to civil servants and the debt is an auto deduction method).
This is kind of price for you should be start collecting if you are searching for a long-term, steady, prospect future business, good dividend payout counter/stock... Always remember what warren has quoted to every "investor"... However, if you are a trader this shouldn't be a counter you should consider about
hebat...naik semula....tempias ekonomi, tak menggugat kestabilan nilai saham penbankan...mata sakit dah sembuh....minggu lepas langit merudum tapi minggu ini, langit cerah betul bak bidadari.
Amongst our 13 stocks, RCE Capital is one of our long standing stocks. It has given us the comfort of sleeping well every night for past 12Q with an ever performing QRs. It’s a steal at current price.
RCECAP is not regulated under Bank Negara, so shouldn't be affected by the 6 months moratorium as compared to banks which should be a good news, some more theirs are mainly personal loans, not housing loans or hire purchase. Major customers are civil servants which are generally unaffected during this Covid-19 pandemic as they are still receiving their salary and even government financial assistance. So in my opinion, RCECAP should outperform the banking stocks in the near term in terms of growth and dividend yield. Correct me if I am wrong, just sharing my thoughts.
@dendron you are right, furthermore, civil servant salary is deducted first for loan repayment to rcecap before the salary reach civil servant. This is beautiful part of it.
Yes. I believe you. With better results, dividend for full year should be at least 11 sens compared to 9 sens for previous year. At closing price of 1.76, the dividend yield is about 6.25%. The PE should be less than 6 at current price. The NTA is about 1.95 and hence the price over NTA is around 90% With expected EPS of 32 sens and dividend of 11 sens, the payout ratio is only 35%. Hence a lot of earnings going back to reserves. Investing in this counter is far better than putting money in bank.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
DTZW 1882
341 posts
Posted by DTZW 1882 > 2020-02-18 23:57 | Report Abuse
thanks Rcecap~~ really best counter ever~~